Not since summer of 2020 when I was trying to get info about the S-1 which was eventually made effective:
SEC Ombudsman Matter Management System (OMMS) Submission - Matter ID Number 20200807-00004113
Mon, Aug 10, 2020 8:03 pm
Ombudsman OMMS (ombudsmanomms@sec.gov)
To:you Details
U.S. SECURITIES AND
EXCHANGE COMMISSION
Dear Dr. Johnson,
Thank you for contacting me and the Investor Advocate with your concerns relating to the status of a registration statement filed by Generex Biotechnology Corporation (GNBT).
For ease of reference, all publicly available SEC filings and information for Generex Biotechnology Corporation, including its most recent Form 8-K filed on August 7, 2020, are available for your review on the SEC's EDGAR system at https://www.sec.gov/cgi-bin/browse-edgar?comp...getcompany.
As an investor, you will need to contact Generex Biotechnology Corporation directly to request additional information relating to the review and status of its registration statement. The SEC is unable to provide you with any information beyond what is publicly available through the SEC's EDGAR system. The CEO and CFO, and designated employees, legal counsel, and/or directors of a company are typically aware of information or circumstances impacting the company’s SEC filings, including outstanding questions or comments from the SEC or the status of registration statement filing reviews.
In general, however, once a company has resolved all Division of Corporation Finance questions or comments on a registration statement, the company may then request that the registration statement be declared effective so that it can proceed with the transaction. When taking that action, the Division of Corporation Finance provides public notice on the SEC’s EDGAR system that the registration statement is effective. Additional information on what occurs during the SEC filing review process is available at https://www.sec.gov/divisions/corpfin/cffilingreview.htm.
The Securities and Exchange Commission considers issues relating to smaller issuers to be important, and appreciates hearing your views. SEC staff take the review of filing and disclosure documents, including those of smaller issuers, extremely seriously. I trust that contacting Generex Biotechnology Corporation directly, and reviewing the information available to you on https://www.sec.gov/cgi-bin/browse-edgar?comp...getcompany, will help answer your remaining questions and concerns.
Thank you for contacting me and the Investor Advocate, and thank you for your interest in the work of the Commission.
Kind regards,
Tracey L. McNeil
Ombudsman
U.S. Securities and Exchange Commission
The Ombudsman generally treats matters as confidential, and takes reasonable steps to maintain the confidentiality of communications. The Ombudsman also attempts to address matters without sharing information outside of the Ombudsman staff, unless you give the Ombudsman permission to do so. However, the Ombudsman may need to contact other SEC divisions or offices, Self-Regulatory Organizations, entities, and/or individuals and share information without your permission under certain circumstances including, but not limited to: a threat of imminent risk or serious harm; assertions, complaints, or information relating to violations of the securities laws; allegations of government fraud, waste, or abuse; or if required by law, such as pursuant to a court order or Freedom of Information Act request initiated by a third party.
Information provided by the staff via email is informal and is not binding on the staff or the Commission. The information is provided as a service to investors. It is neither a legal representation nor a statement of SEC policy. SEC staff cannot act as your personal representative or attorney. For specific information on protecting your particular rights, or if you feel you need a definitive legal analysis of your particular situation, it may be in your best interest to consult with an attorney who specializes in securities law.
This communication and any attachments may be privileged or confidential. If you are not the intended recipient, you have received this communication in error and any review, dissemination, distribution, copying, or use of this communication is strictly prohibited. In such an event, please notify SEC staff immediately by reply email to Ombudsman@sec.gov or by phone toll-free at 877.732.2001 and immediately delete this communication and all attachments.
Ombudsman
U.S. Securities and Exchange Commission
100 F Street NE | Washington, DC 20549
202.551.3330 | Toll-free: 877.SEC.2001 (877.732.2001) | Fax: 301.847.4722
Ombudsman@sec.gov | https://www.sec.gov/ombudsman
SEC Ombudsman Matter Management System (OMMS) Submission - Matter ID Number 20200807-00004113
Mon, Aug 10, 2020 8:03 pm
Ombudsman OMMS (ombudsmanomms@sec.gov)
To:you Details
U.S. SECURITIES AND
EXCHANGE COMMISSION
Dear Dr. Johnson,
Thank you for contacting me and the Investor Advocate with your concerns relating to the status of a registration statement filed by Generex Biotechnology Corporation (GNBT).
For ease of reference, all publicly available SEC filings and information for Generex Biotechnology Corporation, including its most recent Form 8-K filed on August 7, 2020, are available for your review on the SEC's EDGAR system at https://www.sec.gov/cgi-bin/browse-edgar?comp...getcompany.
As an investor, you will need to contact Generex Biotechnology Corporation directly to request additional information relating to the review and status of its registration statement. The SEC is unable to provide you with any information beyond what is publicly available through the SEC's EDGAR system. The CEO and CFO, and designated employees, legal counsel, and/or directors of a company are typically aware of information or circumstances impacting the company’s SEC filings, including outstanding questions or comments from the SEC or the status of registration statement filing reviews.
In general, however, once a company has resolved all Division of Corporation Finance questions or comments on a registration statement, the company may then request that the registration statement be declared effective so that it can proceed with the transaction. When taking that action, the Division of Corporation Finance provides public notice on the SEC’s EDGAR system that the registration statement is effective. Additional information on what occurs during the SEC filing review process is available at https://www.sec.gov/divisions/corpfin/cffilingreview.htm.
The Securities and Exchange Commission considers issues relating to smaller issuers to be important, and appreciates hearing your views. SEC staff take the review of filing and disclosure documents, including those of smaller issuers, extremely seriously. I trust that contacting Generex Biotechnology Corporation directly, and reviewing the information available to you on https://www.sec.gov/cgi-bin/browse-edgar?comp...getcompany, will help answer your remaining questions and concerns.
Thank you for contacting me and the Investor Advocate, and thank you for your interest in the work of the Commission.
Kind regards,
Tracey L. McNeil
Ombudsman
U.S. Securities and Exchange Commission
The Ombudsman generally treats matters as confidential, and takes reasonable steps to maintain the confidentiality of communications. The Ombudsman also attempts to address matters without sharing information outside of the Ombudsman staff, unless you give the Ombudsman permission to do so. However, the Ombudsman may need to contact other SEC divisions or offices, Self-Regulatory Organizations, entities, and/or individuals and share information without your permission under certain circumstances including, but not limited to: a threat of imminent risk or serious harm; assertions, complaints, or information relating to violations of the securities laws; allegations of government fraud, waste, or abuse; or if required by law, such as pursuant to a court order or Freedom of Information Act request initiated by a third party.
Information provided by the staff via email is informal and is not binding on the staff or the Commission. The information is provided as a service to investors. It is neither a legal representation nor a statement of SEC policy. SEC staff cannot act as your personal representative or attorney. For specific information on protecting your particular rights, or if you feel you need a definitive legal analysis of your particular situation, it may be in your best interest to consult with an attorney who specializes in securities law.
This communication and any attachments may be privileged or confidential. If you are not the intended recipient, you have received this communication in error and any review, dissemination, distribution, copying, or use of this communication is strictly prohibited. In such an event, please notify SEC staff immediately by reply email to Ombudsman@sec.gov or by phone toll-free at 877.732.2001 and immediately delete this communication and all attachments.
Ombudsman
U.S. Securities and Exchange Commission
100 F Street NE | Washington, DC 20549
202.551.3330 | Toll-free: 877.SEC.2001 (877.732.2001) | Fax: 301.847.4722
Ombudsman@sec.gov | https://www.sec.gov/ombudsman
2
